Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Post by Ingiboyon Oct 18, 2023 12:02pm
143 Views
Post# 35689162

Questions

QuestionsSo many questions come to mind:

 What will Shiseido do now that they have the green light to market the hair restoration tecnology in Asia ?  
* Did their most recent Trial prove out the technology ? 
* Is it enough to take it to market in Asia ?
* Are they interested in acquiring the global rights from Replicel ?
I would assume with this latest setback that Jamie and Andrew would push for a deal with Shiseido.

What is happening with Mainpointe Pharmaceutical ?
* Are the funding the final development of the device ?
* Are they seeking a North American manufacturer ?
* How far away are they from seeking FDA Approval ?

What is happening with Yofoto ?
* Is the same thing happening with Yofoto that happened with Shiseido ?
* Why do we hear nothing from Replicel regarding their relationship with Yofoto ?

Jamie & Andrew
* Did they have a plan B if the Arbitration went against Replicel ?
* Do they have an appetite to continue funding the company ?

It is time for a detailed update of where Replicel goes from here and we need it now !



<< Previous
Bullboard Posts
Next >>